Clinical trial · Observational
Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2α and LTC4 Levels
NCT01811199CI-TRIAL-00009723unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hypothesis: Dexamethasone reduces postoperative emesis in thyroidectomy and mastectomy patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Number of participants will be evaluated to show effect of dexamethasone in reducing postoperative emesis
- timeFrame
- up to 3 days
- description
- participants will be followed for the duration of hospital stay, till they are discharged in avarage 3 days for postoperative emesis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * breast and thyroid cancer patients no neoadjuvant treated no NSAID or steroid usage heallthy volunteers, signed the informed consent Exclusion Criteria: * ones who did not sign the consent form NSAID or steroid users
References
Publications (0)
Data not yet available
No reference posted for this study.